Clinical Trends for October 2017

Ryan Syrek


October 27, 2017

Clinical Trend of the Week (October 7-13): Verzenio

US Food and Drug Administration (FDA) approval of a drug designed to treat a serious condition has once again resulted in this week's top search term. Abemaciclib (Verzenio, Eli Lilly) has become the third FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitor designed for use in breast cancer, joining palbociclib (Ibrance, Pfizer) and ribociclib (Kisqali, Novartis). What sets abemaciclib apart is that it can be administered as a stand-alone treatment to patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced or metastatic breast cancer who were previously treated with endocrine therapy and chemotherapy. The popularity of searches for this term reflects the severity of the condition, as breast cancer remains the most frequently diagnosed life-threatening cancer in women and the leading cause of cancer death among women worldwide.

For more information on breast cancer, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.